DOCSLIB.ORG

The Role of Integrin Αvβ8 on Human Monocytes and Macrophages in Intestinal Immune Homeostasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Integrin Αvβ8 on Human Monocytes and Macrophages in Intestinal Immune Homeostasis The role of integrin αvβ8 on human monocytes and macrophages in intestinal immune homeostasis A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2018 Elinor Elizabeth Shuttleworth School of Biological Sciences TABLE OF CONTENTS Chapter 1: Introduction .................................................................................. 15 1.1. Introduction ..................................................................................................... 15 1.2. Intestinal barrier function ............................................................................... 15 1.2.1. Intestinal epithelial layer ............................................................................. 17 1.2.2. PRR function in IECs .................................................................................. 19 1.2.3. Intestinal mucus layer ................................................................................. 20 1.3. Intestinal innate immunity .............................................................................. 20 1.3.1. Monocytes and Macrophages .................................................................... 21 1.3.2. Dendritic cells ............................................................................................. 35 1.4. Intestinal adaptive immunity .......................................................................... 41 1.4.1. Intestinal T cells .......................................................................................... 42 1.4.2. Intestinal B cells .......................................................................................... 46 1.4.3. Homing and localisation of intestinal T and B cells .................................... 47 1.5. Control of TGF-β mediated intestinal immune tolerance ............................ 48 1.5.1. The role of αvβ8 mediated TGF-β activation in immune homeostasis ....... 53 Chapter 2 Materials and Methods .................................................................. 58 2.1. Quantifying expression of integrin αvβ8 on peripheral blood mononuclear cells (PBMCs) ......................................................................................................... 58 2.1.1. Peripheral blood collection ......................................................................... 58 2.1.2. PBMC isolation ........................................................................................... 58 2.1.3. PBMC staining for flow cytometry ............................................................... 58 2.1.4. β8 binding antibody-fluorochrome conjugation ........................................... 60 2.1.5. CD14+ monocyte isolation ......................................................................... 61 2.1.6. RNA synthesis for ITGB8 qPCR ................................................................. 61 2.1.7. cDNA synthesis for ITGB8 qPCR ............................................................... 62 2.1.8. ITGB8 qPCR ............................................................................................... 62 2.2. Investigating factors influencing expression of integrin αvβ8 on peripheral blood mononuclear cells (PBMCs) ....................................................................... 63 2.2.1. PBMC and monocyte cytokine treatment ................................................... 63 2.2.2. PBMC and monocyte TLR ligand treatment ............................................... 63 2.3. Investigating function of αvβ8 on peripheral blood mononuclear cells (PBMCs) .................................................................................................................. 64 2.3.1. TGFβ activation reporter cell co-culture assay ........................................... 64 2.3.2. PBMC and monocyte treatment with anti-TGF-β antibody or anti-αvβ8 antibody ................................................................................................................ 65 2.3.3. Flow cytometry to assess treated CD14+ monocyte phenotype ................ 65 2.4. Quantifying expression and function of integrin αvβ8 on MDM ................. 65 2.4.1. MDM culture from CD14+ monocytes ........................................................ 65 2.4.2. MDM staining for flow cytometry ................................................................ 66 2.4.3. IL-10 ELISA ................................................................................................ 66 2.4.4. Phagocytosis assay .................................................................................... 66 2.4.5. MDM treatment with neutralising antibodies or TLR ligands ...................... 67 2.5. Bioenergetic analysis of MDMs ..................................................................... 67 2.5.1. MDM culture for bioenergetic analysis ....................................................... 67 2.5.2. MDM treatment for bioenergetic analysis ................................................... 68 2.5.3. Bioenergetic analysis using the Seahorse XF96 analyser ......................... 68 2.5.3. Protein quantification using the Bicinchoninic Acid (BCA) assay ............... 69 2.5.4. Seahorse data analysis .............................................................................. 69 2.6. General data analysis ..................................................................................... 70 Chapter 3: Integrin αvβ8 mediated TGF-β activation in human monocytes .......................................................................................................................... 71 2 3.1. Introduction ..................................................................................................... 71 3.2. Results ............................................................................................................. 71 3.2.1. Flow cytometry gating protocols to identify integrin αvβ8 on human PBMC .............................................................................................................................. 71 3.2.2. Expression of integrin αvβ8 on peripheral leucocyte populations .............. 74 3.2.3. Validation of results utilising other integrin β8 staining strategies .............. 77 3.2.4. qPCR analysis of PBMC ITGB8 expression .............................................. 82 3.2.5. Effects of cytokine treatment on PBMC integrin αvβ8 expression ............. 84 3.2.6. Effects of TLR ligand treatment on PBMC integrin αvβ8 expression ........ 89 3.2.7. Integrin αvβ8-dependent TGF-β activation by monocytes .......................... 90 3.2.8. Alterations in CD16 expression in TGF-β, TGF-β blocking and integrin αvβ8 blocking antibody-treated monocytes ................................................................... 94 3.3. Discussion ....................................................................................................... 98 Chapter 4: Integrin αvβ8 mediated TGF-β activation in human macrophages ................................................................................................. 105 4.1. Introduction ................................................................................................... 105 4.2. Results ........................................................................................................... 105 4.2.1. Characterisation of human GM-CSF and M-CSF MDM phenotype ......... 105 4.2.2. Expression of integrin αvβ8 on human MDMs .......................................... 106 4.2.3. Mechanisms governing integrin αvβ8 expression on human MDMs ........ 111 4.2.4. Investigating the role of integrin αvβ8 expression in human MDM phenotype ............................................................................................................................ 112 4.3. Discussion ..................................................................................................... 120 Chapter 5: The role of metabolism in determining macrophage phenotype ........................................................................................................................ 126 5.1. Introduction ................................................................................................... 126 5.2. Results ........................................................................................................... 127 5.2.1 Establishing a protocol for bioenergetics analysis of human MDMs .......... 127 5.2.2. Establishing the bioenergetics profile of human GM-CSF and M-CSF MDMs ................................................................................................................................... 131 5.2.3. Investigating factors which alter the bioenergetics profile of human MDMs ................................................................................................................................... 133 5.3. Discussion ..................................................................................................... 145 Chapter 6. Discussion .................................................................................. 152 6.1. TGF-β activation in inflammation and intestinal immune homeostasis .. 152 6.2 TGF-β in fibrosis ............................................................................................. 154 6.3. TGF-β in cancer ............................................................................................. 156 6.4. Personalised therapy in IBD ......................................................................... 159 References ....................................................................................................
Load more

Recommended publications
  • Serum Scd163 As a Biomarker of Adipose Tissue Inflammation in Obstructive Sleep Apnoea Patients: Limits and Perspectives
    AGORA | CORRESPONDENCE Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives To the Editor: Recently, MURPHY et al. [1] demonstrated, through a challenging animal, cellular and human translational approach, that intermittent hypoxia induces a pro-inflammatory activation of adipose tissue macrophages (ATMs), promoting insulin resistance. They confirmed that intermittent hypoxia lowers insulin-mediated glucose uptake in 3T3-L1 adipocytes, and evidenced the interrelationship between inflammation and insulin resistance in the adipose tissue of mice exposed to intermittent hypoxia. They then measured the concentration of serum soluble CD163 (sCD163), an assumed pro-inflammatory biomarker reflecting macrophage activation, in obstructive sleep apnoea (OSA) patients classified according to their BMI and apnoea/hypopnoea index (AHI). This is the first time serum sCD163 has been evaluated in OSA patients, and its association with AHI is promising. With the aim of enhancing its relevance in further studies, we wish to discuss the following points. 1) Activation of adipose tissue macrophages (ATMs) towards M1 phenotype in OSA patients. MURPHY et al. [1] made the assumption that circulating sCD163 levels in OSA patients reflect the intermittent hypoxia-dependent polarisation of ATMs towards a M1 phenotype. As appropriately cited, KRAČMEROVÁ et al. [2] showed that circulating sCD163 concentrations are associated with both macrophage content in human adipose tissue, and insulin sensitivity. However, the assumption that serum sCD163 reflects such a polarisation based on the ADAM-17-dependent cleavage, as hypothesised by ETZERODT et al. [3], is unconvincing since only shown in HEK293 cells. Human ATMs are characterised by a high expression of CD163 which, in contrast, is weakly expressed in differentiated M1 macrophages [4].
    [Show full text]
  • A61K9/00 (2006.01) G01N 2 7/447 (2006.01) Chusetts 02139 (US)
    ( (51) International Patent Classification: (74) Agent: SCARR, Rebecca B. et al.; McNeill Baur PLLC, C07K 16/28 (2006.01) A61K 35/00 (2006.01) 125 Cambridge Park Drive, Suite 301, Cambridge, Massa¬ A61K9/00 (2006.01) G01N 2 7/447 (2006.01) chusetts 02139 (US). A61K9/19 (2006.01) C07K 19/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection av ailable) . AE, AG, AL, AM, PCT/US2020/036035 AO, AT, AU, AZ , BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 04 June 2020 (04.06.2020) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, 62/857,364 05 June 2019 (05.06.2019) US TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. 62/906,862 27 September 2019 (27.09.2019) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: SEATTLE GENETICS, INC. [US/US]; kind of regional protection available) . ARIPO (BW, GH, 21823 30th Drive SE, Bothell, Washington 98021 (US).
    [Show full text]
  • In Vivo Imaging of Tgfβ Signalling Components Using Positron
    REVIEWS Drug Discovery Today Volume 24, Number 12 December 2019 Reviews KEYNOTE REVIEW In vivo imaging of TGFb signalling components using positron emission tomography 1 1 2 Lonneke Rotteveel Lonneke Rotteveel , Alex J. Poot , Harm Jan Bogaard , received her MSc in drug 3 1 discovery and safety at the Peter ten Dijke , Adriaan A. Lammertsma and VU University in 1 Amsterdam. She is Albert D. Windhorst currently finishing her PhD at the VU University 1 Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands Medical Center (VUmc) 2 under the supervision of A. Pulmonary Medicine, Institute for Cardiovascular Research, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands D. Windhorst and Adriaan A. Lammertsma. Her 3 research interest is on the development of positron Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The emission tomography (PET) tracers that target Netherlands selectively the activin receptor-like kinase 5 in vitro and in vivo. Alex J. Poot obtained his The transforming growth factor b (TGFb) family of cytokines achieves PhD in medicinal chemistry homeostasis through a careful balance and crosstalk with complex from Utrecht University. As postdoctoral researcher at signalling pathways. Inappropriate activation or inhibition of this pathway the VUmc, Amsterdam, he and mutations in its components are related to diseases such as cancer, developed radiolabelled anticancer drugs for PET vascular diseases, and developmental disorders. Quantitative imaging of imaging. In 2014, he accepted a research expression levels of key regulators within this pathway using positron fellowship from Memorial Sloan Kettering Cancer 13 emission tomography (PET) can provide insights into the role of this Center, New York to develop C-labelled probes for tumour metabolism imaging with magnetic resonance in vivo pathway , providing information on underlying pathophysiological imaging (MRI).
    [Show full text]
  • The Role of Tumor Necrosis Factor-Like Weak Inducer of Apoptosis in Atherosclerosis Via Its Two Different Receptors (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 891-897, 2017 The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors (Review) HENGDAO LIU1,2, DAN LIN3, HONG XIANG1, WEI CHEN1, SHAOLI ZHAO1,4, HUI PENG1, JIE YANG1, PAN CHEN1, SHUHUA CHEN1 and HONGWEI LU1,2 1Center for Experimental Medical Research; 2Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013; 3Qingdao Center for Disease Control and Prevention, Qingdao, Shandong 266033; 4Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China Received May 3, 2016; Accepted March 31, 2017 DOI: 10.3892/etm.2017.4600 Abstract. At present, it is commonly accepted that athero- 1. Introduction sclerosis is a chronic inflammatory disease characterized by disorder of the arterial wall. As one of the inflammatory cyto- Atherosclerosis remains a major global challenge (1). The kines of the tumor necrosis factor superfamily, tumor necrosis World Health Organization statistics data suggest that, by factor-like weak inducer of apoptosis (TWEAK) participates 2020, atherosclerosis will be the most common cause of death in the formation and progression of atherosclerosis. TWEAK, and morbidity in both developed and developing countries (2). when binding to its initial receptor, fibroblast growth factor Atherosclerosis has long been studied as a chronic inflamma- inducible molecule 14 (Fn14), exerts adverse biological func- tory disorder of the arterial wall, which involves numerous tions in atherosclerosis, including dysfunction of endothelial cytokines. Accumulating data suggests that one of the cyto- cells, phenotypic change of smooth muscle cells and inflam- kines, tumor necrosis factor-like weak inducer of apoptosis matory responses of monocytes/macrophages.
    [Show full text]
  • Macrophage Activation Markers, CD163 and CD206, in Acute-On-Chronic Liver Failure
    cells Review Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure Marlene Christina Nielsen 1 , Rasmus Hvidbjerg Gantzel 2 , Joan Clària 3,4 , Jonel Trebicka 3,5 , Holger Jon Møller 1 and Henning Grønbæk 2,* 1 Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus N, Denmark; [email protected] (M.C.N.); [email protected] (H.J.M.) 2 Department of Hepatology & Gastroenterology, Aarhus University Hospital, 8200 Aarhus N, Denmark; [email protected] 3 European Foundation for the Study of Chronic Liver Failure (EF-CLIF), 08021 Barcelona, Spain; [email protected] (J.C.); [email protected] (J.T.) 4 Department of Biochemistry and Molecular Genetics, Hospital Clínic-IDIBAPS, 08036 Barcelona, Spain 5 Translational Hepatology, Department of Internal Medicine I, Goethe University Frankfurt, 60323 Frankfurt, Germany * Correspondence: [email protected]; Tel.: +45-21-67-92-81 Received: 1 April 2020; Accepted: 4 May 2020; Published: 9 May 2020 Abstract: Macrophages facilitate essential homeostatic functions e.g., endocytosis, phagocytosis, and signaling during inflammation, and express a variety of scavenger receptors including CD163 and CD206, which are upregulated in response to inflammation. In healthy individuals, soluble forms of CD163 and CD206 are constitutively shed from macrophages, however, during inflammation pathogen- and damage-associated stimuli induce this shedding. Activation of resident liver macrophages viz. Kupffer cells is part of the inflammatory cascade occurring in acute and chronic liver diseases. We here review the existing literature on sCD163 and sCD206 function and shedding, and potential as biomarkers in acute and chronic liver diseases with a particular focus on Acute-on-Chronic Liver Failure (ACLF).
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Interleukin-9 Regulates Macrophage Activation in the Progressive Multiple Sclerosis Brain
    Donninelli et al. Journal of Neuroinflammation (2020) 17:149 https://doi.org/10.1186/s12974-020-01770-z RESEARCH Open Access Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain Gloria Donninelli1†, Inbar Saraf-Sinik1,2†, Valentina Mazziotti3, Alessia Capone1,4, Maria Grazia Grasso5, Luca Battistini1, Richard Reynolds6, Roberta Magliozzi3,6*† and Elisabetta Volpe1*† Abstract Background: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated. Methods: To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional properties. Results: We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of MS patients.
    [Show full text]
  • How Relevant Are Bone Marrow-Derived Mast Cells (Bmmcs) As Models for Tissue Mast Cells? a Comparative Transcriptome Analysis of Bmmcs and Peritoneal Mast Cells
    cells Article How Relevant Are Bone Marrow-Derived Mast Cells (BMMCs) as Models for Tissue Mast Cells? A Comparative Transcriptome Analysis of BMMCs and Peritoneal Mast Cells 1, 2, 1 1 2,3 Srinivas Akula y , Aida Paivandy y, Zhirong Fu , Michael Thorpe , Gunnar Pejler and Lars Hellman 1,* 1 Department of Cell and Molecular Biology, Uppsala University, The Biomedical Center, Box 596, SE-751 24 Uppsala, Sweden; [email protected] (S.A.); [email protected] (Z.F.); [email protected] (M.T.) 2 Department of Medical Biochemistry and Microbiology, Uppsala University, The Biomedical Center, Box 589, SE-751 23 Uppsala, Sweden; [email protected] (A.P.); [email protected] (G.P.) 3 Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Box 7011, SE-75007 Uppsala, Sweden * Correspondence: [email protected]; Tel.: +46-(0)18-471-4532; Fax: +46-(0)18-471-4862 These authors contributed equally to this work. y Received: 29 July 2020; Accepted: 16 September 2020; Published: 17 September 2020 Abstract: Bone marrow-derived mast cells (BMMCs) are often used as a model system for studies of the role of MCs in health and disease. These cells are relatively easy to obtain from total bone marrow cells by culturing under the influence of IL-3 or stem cell factor (SCF). After 3 to 4 weeks in culture, a nearly homogenous cell population of toluidine blue-positive cells are often obtained. However, the question is how relevant equivalents these cells are to normal tissue MCs. By comparing the total transcriptome of purified peritoneal MCs with BMMCs, here we obtained a comparative view of these cells.
    [Show full text]
  • A Cytokine Protein-Protein Interaction Network for Identifying Key Molecules in Rheumatoid Arthritis
    RESEARCH ARTICLE A cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis Venugopal Panga1,2, Srivatsan Raghunathan1* 1 Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase I, Bengaluru, Karnataka, India, 2 Manipal Academy of Higher Education, Manipal, Karnataka, India * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints. Though the current RA therapeutics such as disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics can halt the progression of the disease, none of these would either dramatically reduce or cure RA. So, the identification of OPEN ACCESS potential therapeutic targets and new therapies for RA are active areas of research. Several Citation: Panga V, Raghunathan S (2018) A studies have discovered the involvement of cytokines in the pathogenesis of this disease. cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis. These cytokines induce signal transduction pathways in RA synovial fibroblasts (RASF). PLoS ONE 13(6): e0199530. https://doi.org/ These pathways share many signal transducers and their interacting proteins, resulting in 10.1371/journal.pone.0199530 the formation of a signaling network. In order to understand the involvement of this network Editor: Hua Zhou, Macau University of Science and in RA pathogenesis, it is essential to identify the key transducers and their interacting pro- Technology, MACAO teins that are part of this network. In this study, based on a detailed literature survey, we Received: August 21, 2017 have identified a list of 12 cytokines that induce signal transduction pathways in RASF.
    [Show full text]
  • Silencing of ITGB6 Inhibits the Progression of Cervical Carcinoma Via Regulating JAK/STAT3 Signaling Pathway
    803 Original Article Page 1 of 12 Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway Xiaoxia Zheng, Yanan Zhu, Xiaoping Wang, Yanmei Hou, Yingji Fang Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/Jinan Maternity and Child Care Hospital Affiliated, Jinan, China Contributions: (I) Conception and design: Y Fang; (II) Administrative support: Y Hou; (III) Provision of study materials or patients: X Zheng, Y Zhu, X Wang; (IV) Collection and assembly of data: X Zheng, Y Zhu, X Wang; (V) Data analysis and interpretation: X Zheng, Y Zhu, X Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Yingji Fang. Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/Jinan Maternity and Child Care Hospital Affiliated, No. 2 Jianguo Xiaojingsan Road, Jinan 250001, China. Email:[email protected] . Background: Integrin β6 (ITGB6), a key submonomer of integrin αvβ6, plays an important role in epithelial-to-mesenchymal transition (EMT), wound healing, epithelial-derived tumor growth, fibrosis, and epithelial repair. However, the role of ITGB6 in cervical carcinoma (CC) remains elusive. Methods: The expression levels of ITGB6 in CC tissues and cell lines were determined using quantitative real-time polymerase chain reaction (qRT-PCR). The cell viability, proliferation, apoptosis, migration, and invasion were evaluated by Cell Counting Kit-8 (CCK-8), colony-forming, flow cytometry, and Transwell assay, respectively. The expression of related proteins, including EMT markers and the Janus kinase/signal transducer and activator of transcription (JAK/STAT3) signaling markers, were detected using western blotting.
    [Show full text]
  • BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer Víctor G
    Published OnlineFirst September 19, 2017; DOI: 10.1158/1078-0432.CCR-17-1004 Biology of Human Tumors Clinical Cancer Research BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer Víctor G. Martínez1, Carolina Rubio2,3,Monica Martínez-Fernandez 2,3, Cristina Segovia2,3, Fernando Lopez-Calder on 2, Marina I. Garín4, Alicia Teijeira2, Ester Munera-Maravilla2,5, Alberto Varas1, Rosa Sacedon 1,Felix Guerrero5, Felipe Villacampa3,5, Federico de la Rosa3,5, Daniel Castellano2,6, Eduardo Lopez-Collazo 7,8, Jesus M. Paramio2,3,5, Angeles Vicente1, and Marta Duenas~ 2,3,5 Abstract Purpose: Bladder cancer is a current clinical and social prob- showed that both recombinant BMP4 and BMP4-containing lem. At diagnosis, most patients present with nonmuscle-invasive conditioned media from bladder cancer cell lines favored mono- tumors, characterized by a high recurrence rate, which could cyte/macrophage polarization toward M2 phenotype macro- progress to muscle-invasive disease and metastasis. Bone mor- phages, as shown by the expression and secretion of IL10. Using phogenetic protein (BMP)–dependent signaling arising from a series of human bladder cancer patient samples, we also stromal bladder tissue mediates urothelial homeostasis by pro- observed increased expression of BMP4 in advanced and undif- moting urothelial cell differentiation. However, the possible role ferentiated tumors in close correlation with epithelial–mesenchy- of BMP ligands in bladder cancer is still unclear. mal transition (EMT). However, the p-Smad 1,5,8 staining in Experimental Design: Tumor and normal tissue from 68 tumors showing EMT signs was reduced, due to the increased miR- patients with urothelial cancer were prospectively collected and 21 expression leading to reduced BMPR2 expression.
    [Show full text]